GenoSensor System, showing results of hybridization to biochip (left) and display of data using software (right).
Gene amplification and rearrangements have long been known to occur in cancer cells, and the connection between these events and disease outcome is of great interest, especially in light of the relationship between HER-2/neu amplification and a poor breast cancer prognosis. It is with this backdrop that Vysis, a genomic disease management company based in Downer's Grove, Ill., has been developing genetic tools for research and clinical use. Two products in particular, the GenoSensor™ System, a platform for detecting oncogene amplification, and PathVysion™ HER-2 DNA Probe Kit, a FISH assay for detecting amplification of the HER-2/neu gene, address the growing interest in this area.

The PathVysion HER-2/neu DNA probe is not the first of its kind to be offered. However, this kit is unique in that it includes the means to...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?